{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:40:16Z","timestamp":1739997616132,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1124\/jpet.113.207506","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T04:24:40Z","timestamp":1380255880000},"page":"681-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential Interaction of Neuroleptics with Apomorphine-Induced Behavior in Rats as a Function of Changing Levels of Dopamine Receptor Stimulation"],"prefix":"10.1016","volume":"347","author":[{"given":"Anton A.H.P.","family":"Megens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman M.R.","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Lavreysen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.113.207506_bib1","first-page":"244","article-title":"Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride","volume":"22","author":"Awad","year":"1997","journal-title":"J Psychiatry Neurosci"},{"key":"10.1124\/jpet.113.207506_bib2","first-page":"13","article-title":"Parenteral (im\/iv) droperidol for acutely disturbed behavior in psychotic and non-psychotic individuals","volume":"15","author":"Ayd","year":"1980","journal-title":"Int Drug Ther Newsl"},{"key":"10.1124\/jpet.113.207506_bib3","first-page":"875","article-title":"A multicentric clinical evaluation of pimozide. Preliminary report","volume":"68","author":"Brugmans","year":"1968","journal-title":"Acta Neurol Psychiatr Belg"},{"key":"10.1124\/jpet.113.207506_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(08)60705-9","article-title":"Apomorphine: chemistry, pharmacology, biochemistry","volume":"19","author":"Colpaert","year":"1976","journal-title":"Int Rev Neurobiol"},{"key":"10.1124\/jpet.113.207506_bib5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/bmj.2.6047.1293","article-title":"Prazosin: the first-dose phenomenon","volume":"2","author":"Graham","year":"1976","journal-title":"BMJ"},{"key":"10.1124\/jpet.113.207506_bib6","first-page":"104","article-title":"Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? I. \u201cNeuroleptic activity spectra\u201d for rats","volume":"15","author":"Janssen","year":"1965","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/jpet.113.207506_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.113.207506_bib8","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.207506_bib9","first-page":"335","article-title":"[The neuroleptic syndrome. Attempted systematization of primary and secondary effects observed during neuroleptic treatments]","volume":"60","author":"Lambert","year":"1971","journal-title":"Encephale"},{"key":"10.1124\/jpet.113.207506_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.111.190702","article-title":"Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia","volume":"342","author":"Langlois","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 380","key":"10.1124\/jpet.113.207506_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1994.tb05835.x","article-title":"Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride","volume":"89","author":"Lewander","year":"1994","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1124\/jpet.113.207506_bib12","first-page":"1","article-title":"On remoxipride and raclopride\u2014Two atypical antipsychotics","volume":"76","author":"Lewander","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/jpet.113.207506_bib13","unstructured":"Lewi PJ, Niemegeers CJE, and Gypen LMJ (1977) First hand estimation of the median effective dose (ED50) and its confidence interval, assuming a linear log dose-response function. 1977. Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium. Internal Report N123705\/1."},{"key":"10.1124\/jpet.113.207506_bib14","series-title":"Handbook of Neurochemistry","first-page":"331","article-title":"Neuroleptics","author":"Leysen","year":"1985"},{"key":"10.1124\/jpet.113.207506_bib15","series-title":"Atypical Antipychotics","first-page":"57","article-title":"Receptor profile of neuroleptics","author":"Leysen","year":"2000"},{"key":"10.1124\/jpet.113.207506_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0022-3565(25)11204-4","article-title":"Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)","volume":"260","author":"Megens","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.207506_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0079-6468(08)70306-0","article-title":"Risperidone and related 5HT2\/D2 antagonists: a new type of antipsychotic agent?","volume":"33","author":"Megens","year":"1996","journal-title":"Prog Med Chem"},{"key":"10.1124\/jpet.113.207506_bib18","series-title":"Psychopharmacology: The Fourth Generation of Progress","first-page":"1277","article-title":"Atypical antipsychotic drugs","author":"Meltzer","year":"1995"},{"issue":"Suppl. 358","key":"10.1124\/jpet.113.207506_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0447.1990.tb05306.x","article-title":"A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders","volume":"82","author":"Mendlewicz","year":"1990","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1124\/jpet.113.207506_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/026988118700100304","article-title":"Pharmacological characterization in the rat of grooming and other behavioural responses to the D1 dopamine receptor agonist R-SK&F 38393","volume":"1","author":"Molloy","year":"1987","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.113.207506_bib21","first-page":"3","article-title":"A survey of the most important Janssen neuroleptics","volume":"89","author":"Niemegeers","year":"1993","journal-title":"Cesk Psychiatr"},{"key":"10.1124\/jpet.113.207506_bib22","series-title":"Industrial Pharmacology: I. Neuroleptics","first-page":"98","article-title":"Pre-clinical neuropsychopharmacology of neuroleptics. 4. Prediction of side effects","author":"Niemegeers","year":"1974"},{"key":"10.1124\/jpet.113.207506_bib23","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/0024-3205(79)90096-1","article-title":"A systematic study of the pharmacological activities of dopamine antagonists","volume":"24","author":"Niemegeers","year":"1979","journal-title":"Life Sci"},{"key":"10.1124\/jpet.113.207506_bib24","first-page":"221","article-title":"The role of pimozide in clinical psychiatry: a review","volume":"52","author":"Opler","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.113.207506_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.2042-7158.1986.tb04462.x","article-title":"Concentration-response relations for apomorphine effects on heart rate in conscious rats","volume":"38","author":"Paalzow","year":"1986","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.113.207506_bib26","doi-asserted-by":"crossref","first-page":"36625","DOI":"10.1074\/jbc.M110.159954","article-title":"The dopamine D1-D2 receptor heteromer localizes in dynorphin\/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia","volume":"285","author":"Perreault","year":"2010","journal-title":"J Biol Chem"},{"issue":"Suppl. 358","key":"10.1124\/jpet.113.207506_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.1990.tb05307.x","article-title":"A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia","volume":"82","author":"Pflug","year":"1990","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1124\/jpet.113.207506_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004850-199503000-00004","article-title":"Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles","volume":"10","author":"Rammsayer","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.113.207506_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","article-title":"Targeting the dopamine D2 receptor in schizophrenia","volume":"10","author":"Seeman","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/jpet.113.207506_bib30","first-page":"483","article-title":"Plasma levels of apomorphine following intravenous, intraperitoneal and oral administration to mice and rats","volume":"24","author":"Smith","year":"1979","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1124\/jpet.113.207506_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1152\/physrev.1992.72.3.825","article-title":"Ethology and neurobiology of grooming behavior","volume":"72","author":"Spruijt","year":"1992","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.113.207506_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0447.1992.tb03286.x","article-title":"A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia","volume":"86","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"10.1124\/jpet.113.207506_bib33","series-title":"Encyclopedia of Statistical Science","first-page":"236","article-title":"Statistical methods in bioassay. Estimation of relative potency from quantal responses","author":"Tsutakawa","year":"1982"},{"key":"10.1124\/jpet.113.207506_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.npp.1301071","article-title":"Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways","volume":"32","author":"Urban","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 358","key":"10.1124\/jpet.113.207506_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0447.1990.tb05310.x","article-title":"Experiences of long-term treatment with remoxipride: efficacy and tolerability","volume":"82","author":"W\u00e5linder","year":"1990","journal-title":"Acta Psychiatr Sc Suppl"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652428842X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652428842X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.113.207506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:20:36Z","timestamp":1739996436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652428842X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S002235652428842X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.113.207506","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Interaction of Neuroleptics with Apomorphine-Induced Behavior in Rats as a Function of Changing Levels of Dopamine Receptor Stimulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.113.207506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}